Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Springe zu: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2013 | 2011
Anzahl der Publikationen: 8

2021

Witzens-Harig, Mathias; Viardot, Andreas; Keller, Ulrich; Wosniok, Julia; Deuster, Oliver; Klemmer, Jennifer; Geueke, Anne-Marie; Meissner, Julia; Ho, Anthony D.; Atta, Johannes; Marks, Reinhard; La Rosee, Paul; Buske, Christian; Dreyling, Martin H. und Hess, Georg (2021): The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. In: Hemasphere, Bd. 5, Nr. 10, e636

2020

Hess, Georg; Wagner, Karola; Keller, Ulrich; La Rosee, Paul; Atta, Johannes; Hübel, Kai; Lerchenmueller, Christian; Schoendube, Daniel; Witzens-Harig, Mathias; Ruckes, Christian; Medler, Christoph; Oordt, Christina van; Klapper, Wolfram; Theobald, Matthias und Dreyling, Martin (2020): Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. In: Hemasphere, Bd. 4, Nr. 3, e398

2019

König, Laila; Dreyling, Martin; Duerig, Jan; Engelhard, Marianne; Hohloch, Karin; Viardot, Andreas; Witzens-Harig, Mathias; Kieser, Meinhard; Klapper, Wolfram; Pott, Christiane und Herfarth, Klaus (2019): Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro)-GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial. In: Trials, Bd. 20, Nr. 1, 544

2018

Kriegsmann, Katharina; Kriegsmann, Mark; Bergwelt-Baildon, Michael von; Cremer, Martin und Witzens-Harig, Mathias (2018): NKT cells - New players in CAR cell immunotherapy? In: European Journal of Haematology, Bd. 101, Nr. 6: S. 750-757

2017

Hess, Georg; Rule, Simon; Jurczak, Wojciech; Jerkeman, Mats; Silva, Rodrigo Santucci; Rusconi, Chiara; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Zhou, Wenjiong; Goldberg, Jenna D.; Trambitas, Cristina; Enny, Christopher; Vermeulen, Jessica; Traina, Shana; Chiou, Chiun-Fang; Diels, Joris und Dreyling, Martin (2017): Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. In: Leukemia & Lymphoma, Bd. 58, Nr. 12: S. 2824-2832

2016

Dreyling, Martin; Jurczak, Wojciech; Jerkeman, Mats; Santucci Silva, Rodrigo; Rusconi, Chiara; Trneny, Marek; Offner, Fritz; Caballero, Dolores; Joao, Cristina; Witzens-Harig, Mathias; Hess, Georg; Bence-Bruckler, Isabelle; Cho, Seok-Goo; Bothos, John; Goldberg, Jenna D.; Enny, Christopher; Traina, Shana; Balasubramanian, Sriram; Bandyopadhyay, Nibedita; Sun, Steven; Vermeulen, Jessica; Rizo, Aleksandra und Rule, Simon (2016): Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study. In: Lancet, Bd. 387, Nr. 10020: S. 770-778

2013

Witzens-Harig, Mathias; Memmer, Marie Luise; Dreyling, Martin und Hess, Georg (2013): A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial. In: BMC Cancer 13:308 [PDF, 223kB]

2011

Witzens-Harig, Mathias; Hensel, Manfred; Unterhalt, Michael und Herfarth, Klaus (2011): Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. In: BMC Cancer 11:87 [PDF, 278kB]

Diese Liste wurde am Sat Mar 23 22:51:50 2024 CET erstellt.